Optimizing the immunogenicity of HIV primeboost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
PLOS ONE; 13 (6), 2018
Although there has been a decline in the number of new human immunodeficiency virus (HIV) infections over the years, millions of people continue to be exposed and infected [1]. More than 200 HIV vaccine phase I and II, and 6 efficacy trials have been conducted [2, 3]. The RV144 Thai trial is the only tri...